Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Items 701–793 of 793
Lithovius, R. (2015) · Helda - University of Helsinki Institutional Repository
Physical activity and diabetic complications in patients with type 1 diabetes
Wadén, J. (2010) · Helda - University of Helsinki Institutional Repository · Cited by 2
Diabetes technology and treatment in the paediatric age group
Shalitin, S., & Chase, H. P. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02857.x · Cited by 1
Clinical studies of glucose variability and hypoglycemia in adult patients with type 1 diabetes
Bragd, J. (2011) · Figshare · Cited by 2
Changes in cardiac repolarisation during hypoglycaemia in type 1 diabetes
Christensen, T. F. (2010)
The Hypoglycemia Evaluated Mistakenly as Cerebrovascular Disease
Coşkun, D., Mahli, A., Camgoz, N., Koksal, F., Tarhan, B., & Karabıyık, L. (2011) · Journal of Neurology Research · doi:10.4021/jnr.v1i1.17
“Glucose counter regulatory mechanisms have generally been found to be intact early in the course of type II DM [10, 11].”
BackgroundDesign of a Data Management Tool for the Diabetes Technology Center
Chhaya, T., Rosenthal, K., & Yang, N. (2007) · Systems and Information Engineering Design Symposium · doi:10.1109/sieds.2007.4374004
“Hypoglycemic Associated Autonomic Failure (HAAF) occurs when a person’s hormonal response to counteract hypoglycemia lessens with each drop in blood glucose [1].”
BackgroundJournées Internationales d’Endocrinologie Clinique
Klotz, H.-P. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344193
Joint Modeling of Clinical Efficacy and Safety with an Application to Diabetes Studies
Yang, Z., Shen, W., & Fu, H. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.813520
“Because the symptoms of hypoglycemia are unpleasant to patients and may lead to severe consequences, hypoglycemia represents a limiting factor to achieve good glycemic control (Cryer, 2002; Korytkowski, 2002).”
BackgroundRenda, A. M. G. F., & Spadea, G. C. F. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000128
“In elderly patients, insulin therapy should not be avoided but custom not to pay to achieve optimal glycemic targets with a hypoglycemic risk at acceptably high [30].”
BackgroundPsychologische implicaties van type-2-diabetes mellitus
Hogenelst, M. H. E., & Snoek, F. J. (2010) · Bijblijven · doi:10.1007/bf03088755
Hypoglycaemia and cardiovascular disease. The fatal linkage
Conget, I. (2011) · Avances en Diabetología · doi:10.1016/s1134-3230(11)70006-0
McCall, A. L. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0032-6
“Did it matter that hypoglycemia was less in the glargine group? As Cryer [ 5 ] has argued, hypoglycemia is the primary barrier for achieving recommended glycemic targets for many patients, both for type 1 and for type 2 diabetes treated with insulin.”
BackgroundAn Innovative Approach for Predicting Severe Hypoglycemia
Siminerio, L. M. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.1.18
STRATEGIES TO MANAGE POST- EXERCISE GLYCAEMIA IN TYPE 1 DIABETES
Campbell, M. D. (2014) · Northumbria Research Link (Northumbria University)
Protocolo terap?utico de la hipoglucemia
Gonzlez, J. P. M., Martín-Oterino, J.-Á., Prez, E. P., & Bóveda, N. C. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73231-4 · Cited by 2
Breton, M. D., Farhy, L. S., Penberthy, J. K., & Kovatchev, B. P. (2006) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2006.260113 · Cited by 1
“Consequently hypoglycemia has been identified as the primary barrier to optimal diabetes management [ 4 ].”
BackgroundDiabetes-Related Medication-Induced Hypoglycemia
Tackett, K. L., & Lancaster, C. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009332657
“The risk of developing medication-induced hypoglycemia is associated with either insulin excess as a result of administration of exogenous insulin, stimulation of insulin release with an insulin secretagogue, increased response to insulin as a result of treatment with a sensitizer, or due to polypharmacy.(20) Independ…”
BackgroundHernández-Ruiz, E. A., Castrillón-Estrada, J. A., Acosta‐Vélez, J. G., & Castrillón-Estrada, D. F. (2008)
Hypoglycemia monitoring Monitorización de las hipoglucemias
Rubio, M. M. G., & Cano, M. V. (2008)
Mitrovi, K., Todorovi, S., Vukovi, R., Milenkovi, T., & Zdravkovi, D. (2014)
Review Article Localized in vivo 13 C NMR spectroscopy of the brain
Rolf Gruetter, A., Adriany, G., Choi, I., Henry, P., & Lei, H. (2003)
Contreras, I., & Vehí, J. (2015) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2015.10.170
Tavares, H. M. S. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/43hv-sd90 · Cited by 1
Rodrigues, F. F. L., Rodrigues, L., Neiva, C. M., Teixeira, C. R. D. S., & Zanetti, M. L. (2015)
Lewis-Schroeder, N. F. (2012) · Digital Repository Service (Northeastern University) · doi:10.17760/d20002723
Glucose variability assessment in diabetes mellitus monitoring and control
Fabris, C. (2015) · Padua@research (University of Padova)
Liu, Z. (2011) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tdmj-qv66
Assessment of pancreatic islet cell function and survival
Köhler, M. G. (2015) · Figshare
Siegmund, T. (2013) · Info Diabetologie · doi:10.1007/s15034-013-0468-3
Diabetesnotfälle: Rettung aus Hyper- & Hypoglykämie
Scherbaum, W. A., & Scherbaum, C. R. (2014) · CME · doi:10.1007/s11298-014-1359-1
Insulinothérapie dans le diabète de type2
Molines, L., Darmon, P., Jannot-Lamotte, M.-F., Schaepelynck, P., Tréglia, C., & Raccah, D. (2013) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(13)56365-7
Paty, B. W. (2011) · BMJ Evidence-Based Medicine · doi:10.1136/ebm-2011-100076
Ko, S., Shin, K.-Y., Yong, Y.-M., Ko, S.-H., Yun, J., & Ahn, Y. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(14)70367-5
“Hypoglycemia is a well-known acute complication of diabetes treatment and is considered a main barrier to achieving glycemic goals in patients with type 2 diabetes [20-22].”
BackgroundConthe, P., Artola, S., Goday, A., Abad, M., Capel, M., & García-Losa, M. (2015) · PharmacoEconomics Spanish Research Articles · doi:10.1007/s40277-015-0051-5
Snoek, F. J., & Hogenelst, M. H. E. (2012) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-9890-4_8
Indu, K. C. (2016) · Medical Journal of Shree Birendra Hospital · doi:10.3126/mjsbh.v15i1.15018
Defective Counterregulation and Hypoglycemia Unawareness in
Reno, C. M., Litvin, M., Clark, A. L., & Fisher, S. J. (2013)
Pirolo, R., & Bettiol, A. (2016) · Advances in Pharmacoepidemiology & Drug Safety · doi:10.4172/2167-1052.1000205
“The main purpose of antidiabetic treatment is to avoid hyperglycemic events that may cause neuropathy, nephropathy, cardiovascular complications, retinopathy and diabetic ulcers [1-4].”
Paracrine regulation of glucagon secretion from pancreatic islets
Elliott, A. D. (2014)
Szczęśniak, G., Jaworska, J., Jaworski, T., & Dziemidok, P. (2012) · PubMed
Diabète de type 1 et surplus de poids : au-delà des glucides
Fortin, A., Boudreau, V., RABASA-LHORET, R. P. R., & Gingras, V. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30033-0
The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes
Neumann, U. H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0348695
“In type 1 diabetes and late stage type 2 diabetes, the secretory response of the α-cell to low blood glucose levels is defective, which can lead to hypoglycemic episodes [66].”
BackgroundSomatostatin Receptor Type 2 (SSTR2) Antagonism and Hypoglycemia in Diabetes
Yue, J. T. Y. (2012) · TSpace (University of Toronto)
Running title: Peripheral Insulin Delivery and Hypoglycemia
Gregory, J. M., Kraft, G., Scott, M. F., Neal, D. W., Farmer, B., Hastings, J. R., Allen, E. J., Donahue, E. P., Rivera, N., Winnick, J. J., et al. (2015)
Lin, J., Cheng, J., Yu, X., & Wang, J. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00163
Sugiyama, K., Meguro, S., Saisho, Y., Irie, J., Tanaka, M., & Itoh, H. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e01257
Thangtumpitak, T. (2019) · Srinagarind Medical Journal-ศรีนครินทร์เวชสาร
Examining the Role of Jagn1 in Pancreatic β-Cells
Nosak, C. (2014) · TSpace (University of Toronto)
Wilson, A. (2019) · Stirling Online Research Repository (University of Stirling)
Wang, S., & Tu, Y. (2019) · International Conference on Data Science and Business Analytics (ICDSBA) · doi:10.1109/icdsba48748.2019.00102
“Blackman noticed this and developed the Libich minimum factor law in 1905, and proposed that the maximum state of the ecological factor also has a restrictive factor function, namely the law of limiting factors [7] .”
BackgroundVanGilder, R. L. (2009) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4544
The Hypoglycemia Evaluated Mistakenly as Cerebrovascular Disease
Coşkun (2011) · Journal of Neurology Research · doi:10.4021/jnr15e
Evolution in Overcoming Barriers in Management of Diabetes: Hypoglycemia
Banzal, S., Banzal, S., & Kabadi, U. M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115020 · Cited by 1
“Alternatively, impaired regulation in secretion of all three counter regulatory hormones, exacerbates and perpetuates occurrence of hypoglycemia in subjects with both type 1 and type 2 diabetes [1] [5] [15] [27]-[33].”
BackgroundInfluential(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00987-6
Gupta, K., Deka, S., & Chandolia, B. (2022) · International Journal of Science and Healthcare Research · doi:10.52403/ijshr.20220108
Current literature in diabetes
(2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.248
Brillon, D. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_39
Desarrollo de un Sistema de Decisión basado en Lógica Borrosa para el uso de Bombas de Insulina
Galván, J. B., Recarte, L., & Pérez-Ilzarbe, M. J. (2014) · RISTI - Revista Ibérica de Sistemas e Tecnologias de Informação · doi:10.4304/risti.13.1-15
Insulin, glucagon, and hypoglycemic drugs
Krans, H. M. J. (2004) · Side effects of drugs annual · doi:10.1016/s0378-6080(04)80049-7
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00894-5
Scherbaum, W. A., & Scherbaum, C. R. (2015) · Springer eBooks · doi:10.1007/978-3-662-46521-9_6
INSULINS AND OTHER HYPOGLYCEMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9
Snoek, F. J. (2006) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-9254-4_8
Frier, B. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-850-8_6
Diabetes Technology and Treatment in the Paediatric Age Group
Shalitin, S., & Chase, H. P. (2012) · Wiley eBooks · doi:10.1002/9781118321508.ch11
Bozadjieva, J. A. W. A. E. B.-M. N. (2013) · doi:10.3998/panc.2013.23
Fetian, I. R., Maziukas, R., Pisarcikova, Z., Zechmann, S., Dolinar, M., Dolinar, S., & Villiger, L. (2022) · doi:10.36000//hbt.2022.05.001
Clinical Evaluation of Predisposing Factors of Hypoglycaemia in Diabetic Patients
Rahman, M. M., Talukder, S., Baker, I. M., Das, A., Baset, M. A., & Najnin, F. (2023) · TAJ Journal of Teachers Association · doi:10.3329/taj.v35i2.63763
The Drug-Induced Hypoglycemia in Children: Is Levetiracetam Incriminated?
Elqadiry, R., Fetoui, I., Nassih, H., Bourahouat, A., & Aitssab, I. (2023) · SAS Journal of Medicine · doi:10.36347/sasjm.2023.v09i05.021
Alleviating the fears hypoglycaemia and weight loss among young Muslim people during Ramadan Fasting
Adeniji, A.-R. A., Mustapha, M. J., Nazir, A., Oduoye, M. O., Olaide, Z., & Akilimali, A. (2023) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000375
“Moreover, hypoglycemia has broad rami fi cations for diabetic self-management and is a substantial limiting factor in obtaining adequate glycaemic control [20] .”
BackgroundHow individuals perceive and process diagnostic device errors
Becker, M. Y., & Matt, C. (2024) · Journal of Decision System · doi:10.1080/12460125.2024.2354578 · Cited by 1
(2024) · American Diabetes Association eBooks · doi:10.2337/9781580408363.ch05
Pharmacotherapy of type 1 diabetes - part 1: yesterday
Rendell, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2454280
“The control of ensuing hypoglycemia is the main challenge in regulating the administration of insulin in type 1 diabetes [56].”
Stoia, D., & Focşan, M. (2025) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-94-024-2296-2_4
Mohan, V., Sethi, B. K., Jain, S. M., Sahay, R. K., Balamurugan, R., Murthy, S., Singh, K. P., MENON, S. K., Gadekar, A. V., Salvi, V., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01736-5 · Cited by 1
Bader, S., Ashfaq, A., Mussa, B. M., & Abusanana, S. (2025) · Research Square · doi:10.21203/rs.3.rs-6563191/v1
Li, S., Shan, X., Wei, X., Dai, W., & Cao, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01794-6 · Cited by 1
Mitochondrial movement in pancreatic alpha cells requires Miro2 and is regulated by glucose
Ekstrand, M. H., Nawaz, S., Clark, A., Hastoy, B., & Knudsen, J. G. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110984 · Cited by 1
Arjan, M. K. (2013) · An-Najah University Journal for Research - B (Humanities) · doi:10.35552/0247-027-008-003 · Cited by 1
ZEMB, P. A., & Joulia, F. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6068352
Colson, S. (2015) · theses.fr (ABES) · doi:10.70675/23c1afffz55d4z463cz83d0z47b395734917
“11 l’équilibre glycémique, car elle peut s'accompagner de symptômes désagréables, embarrassants et potentiellement dangereux, tout en provoquant de l’anxiété et de la peur chez le patient et ses aidants (Cryer, 2002 ; Clarke et al., 1998).”
BackgroundA Patient- and Function-Centric Model/Approach for Hypoglycemia Management in Older Adults
Alagiakrishnan, K., Mereu, L., Rahim, G., Ghosh, M., & Vu, A. (2026) · Geriatrics · doi:10.3390/geriatrics11050118
Bader, S., Ashfaq, A., Mussa, B. M., Alawadi, F., Bhamidimarri, P. M., Al-Abadla, Z., & Abusnana, S. (2026) · Acta Neurologica Scandinavica · doi:10.1155/ane/6400429
Liu, V. B., Pho, M., & Wu, Y. N. (2026) · Mathematics in Medical and Life Sciences · doi:10.1080/29937574.2026.2705548
Geelhoed-Duijvestijn, N., Östenson, C. G., Lahtela, J. T., Weitgasser, R., Jensen, M. M., & Timmermans, S. (2014) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-014-0014-5 · Cited by 1
Petty, S. (2013) · Repository@Hull (Worktribe) (University of Hull)
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.